You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
啟明醫療-B(02500.HK)公佈年度業績 毛利升97%至1.95億元 研發開支增加91.3%
格隆匯 03-27 19:43

格隆匯3月27日丨啟明醫療-B(02500.HK)公佈,截至2019年12月31日止年度,公司收入2.33億元人民幣,同比增長102%;毛利1.95億元,同比增長97%;公司擁有人應占虧損3.8億元,虧損同比擴大27%;每股虧損1.22元。

收入增加主要由於Venus A-Valve的市場接受度持續提高,以及公司不斷進行營銷及擴張而令其銷量有所增加。

該年度,集團的研發成本為人民幣2億元(未經審核),同比增加91.3%。上述增加主要由於公司於2018年12月完成收購Keystone後綜合入帳Keystone的財務報表,主要包括Keystone人員開支和臨牀試驗開支所致。

公司稱,公司計劃推進現有的管線產品,進一步擴大公司在結構性心臟病領域的覆蓋範圍,橫向覆蓋所有四個心臟瓣膜,縱向覆蓋瓣膜、CEP、瓣膜成形術球囊到其他輔助裝置。公司將投資於技術創新,加強公司的研發能力以開發新產品及提高我們的競爭力,因為公司相信創新是實現公司成為結構性心臟病經導管解決方案全球領軍企業這一使命的關鍵因素。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account